| Literature DB >> 30894049 |
Aditya Saxena1, Pradeep Tiwari2,3,4, Nitin Wahi1, Arpana Soni2, Ram Chandra Bansiwal2, Anshul Kumar2, Balram Sharma2, Poonam Punjabi2, Nidhi Gupta5, Babita Malik4, Krishna Mohan Medicherla3, Prashanth Suravajhala3, Sandeep Kumar Mathur2.
Abstract
Type 2 diabetes (T2D) is a complex disease with an elusive link between its molecular aetiology and clinical presentation. Although, the role of visceral adipose tissue in insulin-resistance and T2D is known, limited information is available on the role of peripheral-subcutaneous adipose tissue especially in Asian Indians. In this microarray-based study of diabetic and normal glucose tolerant Asian Indians, we generated the transcriptome of their thigh adipose tissue and analyzed differentially expressed genes (DEGs) using weighted gene co-expression network analysis; further we identified perturbed pathways implicated by these DEGs in relevant co-expression modules. We also attempted to link these pathways with known aspects of T2D pathophysiology in terms of their association with some of their intermediate traits, namely; adipocyte size, HOMA-B, HOMA-R, Hb1Ac, insulin, glucose-level, TNF-α, IL-6, VLDLs, LDLs, HDLs, and NEFAs. It was observed that several modules of co-expressed genes show an association with diabetes and some of its intermediate phenotypic traits mentioned above. Therefore, these findings suggest a role of peripheral subcutaneous adipose tissue in the pathophsiology of T2D in Asian Indians. Additionally, our study indicated that the peripheral subcutaneous adipose tissue in diabetics shows pathologic changes characterized by adipocyte hypertrophy and up-regulation of inflammation-related pathways.Entities:
Keywords: Asian Indians; Type 2 diabetes; peripheral adipose tissue; signalling pathway impact analysis; system biology; weighted gene co-expression network analysis
Mesh:
Year: 2019 PMID: 30894049 PMCID: PMC6768216 DOI: 10.1080/21623945.2019.1595269
Source DB: PubMed Journal: Adipocyte ISSN: 2162-3945 Impact factor: 4.534
Inclusion and exclusion criteria for the study subjects.
| Condition | Inclusion criteria | Exclusion criteria |
|---|---|---|
| Diabetic subjects | Non-obese (BMI < 30) type-2 diabetics diagnosed as per American Diabetes Association (ADA, 2012) criteria undergoing femur bone surgery. | Presence of infection, malignancy and drugs affecting body fat/insulin resistance or adipokine expression like glitazones, metformin and glucocorticoids. |
| Non-diabetic | Age and sex-matched non-obese (BMI < 30) normal glucose tolerance subjects undergoing femur bone surgery. | Presence of infection, malignancy and drugs affecting body fat/insulin resistance or adipocytokines expression like glitazones, metformin and glucocorticoids. History of diabetes in first degree relatives. |
PCR primer-pairs used in qPCR.
| S. No. | Gene | Primer pair |
|---|---|---|
| 1 | Forward, 5ʹ- GAGGCAGCGACTCATCTTT-3ʹ and Reverse, 5ʹ-AGCATCTTCACCGTCAGGTC-3’ | |
| 2 | Forward, 5ʹ-TCTCGCTAGGATGCTTTACTCC-3ʹ and Reverse, 5ʹ-CGTTCACAAGCTGTCCTGTC-3’ | |
| 3 | SOS1 | Forward, 5ʹ-CAAGTTCCCCCTAATTTGACAT-3ʹ and Reverse, 5ʹ-CAACCTCCTCCCCCATAATAA-3’ |
| 4 | Forward, 5ʹ-CCTTGAATCTGCCGACTTTT-3ʹ and Reverse, 5ʹ-TGTTATTAAAAATACAGTTCCCCAGA-3’ | |
| 5 | Forward, 5ʹ-GGCTCCACTCAGATCTTTTCC-3ʹ and Reverse, 5ʹ-ATAGGGGCTTCCTGAGCAC-3’ | |
| 6 | Forward, 5ʹ-CCAAGGTGATCTCACACTCCT-3ʹ and Reverse, 5ʹ-AAACCATGTTCTTTGTTTGTTTAAGA-3’ | |
| 7 | Forward, 5ʹ-GCGAAGGCTAAAGGAAAAGG-3ʹ and Reverse, 5ʹ-TCAGGATCTCGATCAGCTTG-3’ | |
| 8 | Forward, 5ʹ-CCAACCGCGAGAAGATGA-3ʹ and Reverse, 5ʹ-CCAGAGGCGTACAGGGATAG-3’ | |
| 9 | Forward, 5ʹ-AACAGAGTGAGCCCTTCTTCA-3ʹ and Reverse, 5ʹ-GGAGGCTGCATCATCGTACT-3ʹ. |
Gender-wise measured anthropometric, and biochemical parameters in both NGT and T2D groups (expressed as means ± SD).
| Gender | Female | Male | ||||
|---|---|---|---|---|---|---|
| Group | NGT | T2D | t test | NGT | T2D | t test |
| Age | 65.80 ± 13.64 | 64.12 ± 8.15 | 0.65 | 61.95 ± 9.07 | 58.87 ± 9.17 | 0.33 |
| Weight (kg) | 52.10 ± 10.17 | 63.12 ± 16.06 | 0.02 | 55.80 ± 6.92 | 63.07 ± 11.02 | 0.04 |
| BMI | 21.49 ± 4.02 | 26.31 ± 6.96 | 0.02 | 20.28 ± 2.80 | 22.73 ± 3.25 | 0.03 |
| W: H | 0.97 ± 0.07 | 0.99 ± 0.10 | 0.50 | 1.03 ± 0.21 | 1.03 ± 0.07 | 0.90 |
| Fasting glucose (mg/dl) | 90.42 ± 12.48 | 183.32 ± 72.45 | 0.00007 | 88.96 ± 9.69 | 204.36 ± 102.13 | 0.0006 |
| Triglyceride | 163.70 ± 79.26 | 154.65 ± 53.17 | 0.68 | 154.32 ± 44.02 | 144.57 ± 55.02 | 0.59 |
| Total cholesterol | 195.60 ± 42.19 | 182.04 ± 35.58 | 0.30 | 180.65 ± 37.41 | 192.63 ± 66.90 | 0.56 |
| HDL | 40.90 ± 8.83 | 41.61 ± 4.00 | 0.75 | 40.47 ± 4.43 | 40.21 ± 7.62 | 0.91 |
| LDL | 87.39 ± 20.63 | 93.05 ± 21.91 | 0.43 | 94.28 ± 19.16 | 95.69 ± 33.11 | 0.89 |
| VLDL | 31.71 ± 8.44 | 51.09 ± 40.88 | 0.07 | 31.22 ± 6.79 | 33.92 ± 10.65 | 0.44 |
| Serum creatinine | 1.04 ± 0.32 | 1.04 ± 0.38 | 1.00 | 0.99 ± 0.17 | 1.08 ± 0.20 | 0.22 |
| HOMA-B | 192.89 ± 252.9 | 115.68 ± 125.97 | 0.24 | 132.87 ± 87.65 | 126.59 ± 126.75 | 0.87 |
| HOMA-R | 2.45 ± 2.13 | 12.30 ± 11.38 | 0.002 | 1.83 ± 1.47 | 11.97 ± 7.16 | 0.00007 |
| Insulin | 11.16 ± 9.89 | 26.22 ± 19.00 | 0.01 | 8.25 ± 5.93 | 24.44 ± 10.77 | 0.00003 |
| Hb1Ac (%) | 5.45 ± 0.62 | 8.17 ± 1.38 | 0.0000002 | 5.32 ± 0.55 | 9.22 ± 2.75 | 0.00007 |
| NEFA (mmol/L) | 0.62 ± 0.30 | 0.63 ± 0.48 | 0.92 | 0.51 ± 0.26 | 0.66 ± 0.43 | 0.26 |
| HsCRP (ng/ml) | 7950.78 ± 5701.0 | 8769.12 ± 4779.9 | 0.64 | 7279.16 ± 5140.79 | 10202.27 ± 4134.99 | 0.07 |
| Leptin (pg/ml) | 8150.77 ± 7945.67 | 19144.99 ± 27723.65 | 0.13 | 7810.80 ± 5691.17 | 8094.73 ± 6584.18 | 0.89 |
| Adiponectin (ng/ml) | 210.71 ± 116.19 | 236.74 ± 239.48 | 0.69 | 183.76 ± 117.78 | 208.99 ± 86.46 | 0.47 |
| IL-6 | 33.33 ± 53.05 | 30.53 ± 33.71 | 0.85 | 22.02 ± 29.45 | 30.34 ± 46.60 | 0.55 |
| TNF-α | 25.42 ± 17.51 | 28.84 ± 35.04 | 0.72 | 32.70 ± 29.63 | 28.75 ± 35.79 | 0.73 |
Gender-wise comparison of adipocyte cell size in both NGT and T2D groups.
| Male | Female | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Diabetics | Non-diabetic | Diabetics | Non-diabetic | ||||||
| Mean | SD | Mean | SD | T test | Mean | SD | Mean | SD | T test |
| 75873.3 | 47100.8 | 72550.4 | 35,412 | 0.82642 | 134491 | 67161.7 | 76443.2 | 48055.2 | 0.00593 |
Gender-wise measured cell infiltration parameters in both NGT and T2D groups.
| Cell infiltration data | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Antibody marker | Male | Female | ||||||||
| Diabetics | Non-diabetic | T test | Diabetics | Non-diabetic | T test | |||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
| CD 44 | 4.78 | 5.76 | 1.4 | 2.67 | 0.19 | 0.39 | 0.69 | 2.5 | 4.47 | 0.14 |
| CD 163 | 8.77 | 7.28 | 3.31 | 2.37 | 0.1 | 4.25 | 5.44 | 8.26 | 10.92 | 0.33 |
| CD 3 | 2.54 | 2.7 | 0.61 | 0.66 | 0.11 | 0.8 | 0.76 | 1.36 | 1.69 | 0.36 |
| HAM 56 | 0.68 | 0.79 | 1.56 | 2.38 | 0.3 | 0.53 | 0.37 | 1.28 | 2.44 | 0.32 |
Figure 1.Consensus gene dendrogram with seven modules constructed using expression profiles of 7186 genes from male and female microarray datasets in the network.
Figure 2.Module-trait relationships in the male and female limb datasets.
Consensus modules showing correlation (P < 0.05) with intermediate traits.
| Male | Female | |||||
|---|---|---|---|---|---|---|
| S. No. | Name of consensus module | Total nodes (genes) | % of genes mapped as differentially regulated | Modules showing correlation ( | % of genes mapped as differentially regulated | Modules showing correlation ( |
| 1 | Turquoise | 4058 | 20.3 | Adipocyte size, hsCRP, LDL | 48.8 | Adipocyte size, phenotype |
| 2 | Green | 77 | 7.2 | hsCRP | 0.1 | – |
| 3 | Brown | 329 | 8.1 | Adipocyte size, hsCRP, Adiponectin, LDL | 0.9 | – |
| 4 | Red | 53 | 7.5 | – | 0.2 | – |
| 5 | Blue | 2212 | 11.0 | – | 46.9 | Adipocyte size, phenotype, Hb1Ac |
| 6 | Yellow | 120 | 31.0 | Disease status | 0.5 | Leptin |
| 7 | Grey | 337 | 14.9 | Adiponectin, insulin | 2.5 | hsCRP, TNF-α, Sr.Cr. |
Top 20 perturbed KEGG signalling pathways implicated by genes in turquoise module.
| S. No. | Pathway | pERT | pG | Status |
|---|---|---|---|---|
| 1 | HIF-1 signalling pathway | 5.00E-06 | 6.60E-05 | Activated |
| 2 | Toll-like receptor signalling pathway | 0.001 | 0.007908 | Activated |
| 3 | cGMP-PKG signalling pathway | 0.009 | 0.051395 | Activated |
| 4 | NF-kappa B signalling pathway | 0.009 | 0.051395 | Activated |
| 5 | p53 signalling pathway | 0.009 | 0.051395 | Inhibited |
| 6 | AMPK signalling pathway | 0.015 | 0.077996 | Activated |
| 7 | Relaxin signalling pathway | 0.027 | 0.124522 | Activated |
| 8 | Estrogen signalling pathway | 0.037 | 0.158983 | Activated |
| 9 | NOD-like receptor signalling pathway | 0.038 | 0.162266 | Activated |
| 10 | Hippo signalling pathway | 0.043 | 0.178302 | Inhibited |
| 11 | AGE-RAGE signalling pathway in diabetic complications | 0.043 | 0.178302 | Activated |
| 12 | Apelin signalling pathway | 0.058 | 0.223144 | Activated |
| 13 | GnRH signalling pathway | 0.075 | 0.26927 | Activated |
| 14 | IL-17 signalling pathway | 0.077 | 0.274424 | Activated |
| 15 | Sphingolipid signalling pathway | 0.082 | 0.287085 | Activated |
| 16 | TGF-beta signalling pathway | 0.087 | 0.299441 | Inhibited |
| 17 | Phospholipase D signalling pathway | 0.088 | 0.301877 | Activated |
| 18 | mTOR signalling pathway | 0.091 | 0.309118 | Activated |
| 19 | Insulin signalling pathway | 0.091 | 0.309118 | Activated |
| 20 | Adipocytokine signalling pathway | 0.565 | 0.887575 | Activated |
Top 10 perturbed KEGG pathways implicated by genes in blue, yellow and brown modules.
| S. No. | Pathway | pERT | pG | Status |
|---|---|---|---|---|
| 1 | Ras signalling pathway | 0.004 | 0.026086 | Inhibited |
| 2 | Hedgehog signalling pathway | 0.011 | 0.060608 | Inhibited |
| 3 | PI3K-Akt signalling pathway | 0.016 | 0.082163 | Inhibited |
| 4 | IL-17 signalling pathway | 0.022 | 0.105968 | Inhibited |
| 5 | Chemokine signalling pathway | 0.048 | 0.193755 | Inhibited |
| 6 | Relaxin signalling pathway | 0.088 | 0.301877 | Inhibited |
| 7 | Neurotrophin signalling pathway | 0.095 | 0.318618 | Activated |
| 8 | Thyroid hormone signalling pathway | 0.11 | 0.3528 | Inhibited |
| 9 | Adrenergic signalling in cardiomyocytes | 0.114 | 0.361557 | Activated |
| 10 | Apelin signalling pathway | 0.116 | 0.365883 | Inhibited |
| 1 | Wnt signalling pathway | 0.117 | 0.368033 | Inhibited |
| 2 | Hippo signalling pathway | 0.576 | 0.893749 | Inhibited |
| 3 | Rap1 signalling pathway | 0.61 | 0.911521 | Inhibited |
| 4 | mTOR signalling pathway | 0.667 | 0.937112 | Inhibited |
| 5 | MAPK signalling pathway | 0.823 | 0.98332 | Activated |
| 6 | Ras signalling pathway | 0.847 | 0.987648 | Activated |
| 7 | AGE-RAGE signalling pathway in diabetic complications | 0.965 | 0.99938 | Activated |
| 8 | TGF-beta signalling pathway | 0.967 | 0.999449 | Activated |
| 9 | PI3K-Akt signalling pathway | 0.979 | 0.999778 | Activated |
| 10 | FoxO signalling pathway | 0.984 | 0.999871 | Activated |
| 1 | IL-17 signalling pathway | 0.019 | 0.094303 | Inhibited |
| 2 | Toll-like receptor signalling pathway | 0.026 | 0.120891 | Inhibited |
| 3 | PI3K-Akt signalling pathway | 0.04 | 0.168755 | Inhibited |
| 4 | Prolactin signalling pathway | 0.159 | 0.451377 | Activated |
| 5 | Wnt signalling pathway | 0.167 | 0.46589 | Activated |
| 6 | Calcium signalling pathway | 0.17 | 0.471233 | Activated |
| 7 | Adipocytokine signalling pathway | 0.174 | 0.478274 | Activated |
| 8 | T cell receptor signalling pathway | 0.283 | 0.640233 | Inhibited |
| 9 | NOD-like receptor signalling pathway | 0.311 | 0.674236 | Activated |
| 10 | Epithelial cell signalling in Helicobacter pylori infection | 0.32 | 0.684619 | Inhibited |